TERT and glioblastoma: A study of 126 GBM patients, showed that the subgroup of patients with wild-type TERT promoter who were also carriers for rs2853669 had longer median survival than those who were non-carriers for rs2853669 (43.5 vs 20.4 months) (Spiegl-Kreinecker et al. 2015).